Emergent BioSolutions (EBS) Change in Account Payables: 2010-2025
Historic Change in Account Payables for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to -$4.0 million.
- Emergent BioSolutions' Change in Account Payables rose 82.61% to -$4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.0 million, marking a year-over-year decrease of 0.33%. This contributed to the annual value of -$33.0 million for FY2024, which is 411.32% down from last year.
- According to the latest figures from Q3 2025, Emergent BioSolutions' Change in Account Payables is -$4.0 million, which was up 61.54% from -$10.4 million recorded in Q2 2025.
- Emergent BioSolutions' Change in Account Payables' 5-year high stood at $31.0 million during Q1 2023, with a 5-year trough of -$23.0 million in Q3 2024.
- For the 3-year period, Emergent BioSolutions' Change in Account Payables averaged around -$3.8 million, with its median value being -$5.4 million (2025).
- Its Change in Account Payables has fluctuated over the past 5 years, first slumped by 1,200.00% in 2021, then spiked by 310.88% in 2023.
- Over the past 5 years, Emergent BioSolutions' Change in Account Payables (Quarterly) stood at -$5.1 million in 2021, then soared by 56.86% to -$2.2 million in 2022, then plummeted by 222.73% to -$7.1 million in 2023, then plummeted by 43.66% to -$10.2 million in 2024, then surged by 82.61% to -$4.0 million in 2025.
- Its Change in Account Payables was -$4.0 million in Q3 2025, compared to -$10.4 million in Q2 2025 and -$5.4 million in Q1 2025.